Syndax Pharmaceuticals (NASDAQ:SNDX) CFO Keith Goldan Sells 1,177 Shares

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith Goldan sold 1,177 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $18.99, for a total value of $22,351.23. Following the completion of the transaction, the chief financial officer owned 139,252 shares in the company, valued at $2,644,395.48. This represents a 0.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Syndax Pharmaceuticals Price Performance

Shares of SNDX stock remained flat at $18.85 during trading hours on Tuesday. The stock had a trading volume of 1,492,655 shares, compared to its average volume of 1,387,019. Syndax Pharmaceuticals, Inc. has a 52 week low of $8.59 and a 52 week high of $25.59. The company has a current ratio of 5.47, a quick ratio of 5.06 and a debt-to-equity ratio of 8.26. The firm has a 50 day moving average of $22.13 and a two-hundred day moving average of $21.20. The company has a market capitalization of $1.67 billion, a P/E ratio of -6.76 and a beta of 0.41.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Thursday, April 30th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.11. Syndax Pharmaceuticals had a negative return on equity of 256.65% and a negative net margin of 111.88%.The company had revenue of $64.86 million for the quarter, compared to analyst estimates of $69.76 million. During the same quarter last year, the company earned ($0.98) earnings per share. The company’s revenue for the quarter was up 224.3% on a year-over-year basis. On average, equities research analysts expect that Syndax Pharmaceuticals, Inc. will post -1.66 earnings per share for the current year.

Institutional Trading of Syndax Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Apis Capital Advisors LLC purchased a new stake in Syndax Pharmaceuticals in the third quarter worth $9,816,000. Palumbo Wealth Management LLC purchased a new stake in Syndax Pharmaceuticals in the fourth quarter worth $1,079,000. Torray Investment Partners LLC purchased a new stake in Syndax Pharmaceuticals in the fourth quarter worth $2,055,000. Keybank National Association OH purchased a new stake in Syndax Pharmaceuticals in the third quarter worth $2,305,000. Finally, SG Americas Securities LLC increased its position in Syndax Pharmaceuticals by 184.5% in the fourth quarter. SG Americas Securities LLC now owns 129,227 shares of the company’s stock worth $2,715,000 after buying an additional 83,801 shares during the last quarter.

Analyst Ratings Changes

SNDX has been the subject of a number of research analyst reports. JPMorgan Chase & Co. increased their price target on Syndax Pharmaceuticals from $33.00 to $45.00 and gave the company an “overweight” rating in a research report on Monday, March 9th. Stifel Nicolaus set a $45.00 price target on Syndax Pharmaceuticals in a research report on Friday, February 27th. UBS Group decreased their price target on Syndax Pharmaceuticals from $38.00 to $37.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Wall Street Zen raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $40.00 price target (down from $48.00) on shares of Syndax Pharmaceuticals in a research report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Syndax Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $42.55.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.